Omeros (NASDAQ:OMER) Research Coverage Started at D. Boral Capital

D. Boral Capital assumed coverage on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $36.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on the stock. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Finally, Rodman & Renshaw began coverage on Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Trading Down 1.1 %

Shares of OMER opened at $10.00 on Monday. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60. The firm has a market capitalization of $579.50 million, a P/E ratio of -4.33 and a beta of 1.96. The firm has a 50-day moving average price of $7.33 and a 200 day moving average price of $5.28.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Wellington Management Group LLP acquired a new stake in shares of Omeros in the third quarter valued at $305,000. Barclays PLC boosted its holdings in Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 51,873 shares during the period. Bank of New York Mellon Corp grew its position in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Omeros during the second quarter worth about $105,000. Finally, SG Americas Securities LLC purchased a new stake in Omeros during the third quarter worth about $80,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.